natgillin/translations-raw huggingface dataset:
Efavirenz does not bind to cannabinoid receptors.
Efavirenz se ne veže na kanabinoidne receptorje.
Interrupting treatment with Atripla should also be considered in case of progressive decline of renal function when no other cause has been identified.
O prekinitvi zdravljenja z zdravilom Atripla je treba razmisliti tudi v primeru progresivnega upada ledvične funkcije, če ni bil ugotovljen noben drug razlog.
It is believed that these symptoms are due to improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Ti simptomi so verjetno posledica izboljšanja imunskega odziva, ki telesu omogoča boj proti okužbam, ki so morda obstajale brez očitnih simptomov.
Tenofovir concentrations not measured, no effect is expected.
Koncentracij tenofovirja niso merili, učinkov ni pričakovati.
What Atripla is and what it is used for
Kaj je zdravilo Atripla in za kaj ga uporabljamo
Your doctor will carefully consider whether to treat you with medicines containing tenofovir and didanosine.
Zdravnik bo skrbno pretehtal, ali vam bo predpisal zdravila, ki vsebujejo tenofovir in didanozin.
• allergic reaction (hypersensitivity) that may cause severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, see section 2)
• alergijska reakcija (preobčutljivost), ki lahko povzroči hude kožne reakcije (Stevens-Johnsonov sindrom, multiformni eritem, glejte poglavje 2);
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Stopping Atripla can seriously affect your response to future treatment.
Prenehanje jemanja zdravila Atripla lahko resno vpliva na vaš odziv na prihodnje zdravljenje.
In particular, severe depression was more common in those with a history of depression.
Zlasti huda depresija je bila pogostejša pri bolnikih z depresijo v anamnezi.
Women of childbearing potential (see below and section 5.3)
Ženske v rodni dobi (glejte spodaj in poglavje 5.3)
Lopinavir concentrations: ↓ 30-40%
Koncentracije lopinavirja: ↓ 30-40 %
• No virus analysed contained the K65R or K70E mutation.
• Noben analiziran virus ni vseboval mutacije K65R ali K70E.
• increased fatty acids (triglycerides), bilirubin or sugar levels in the blood
• povišane ravni maščobnih kislin (trigliceridov), bilirubina ali sladkorja v krvi.
Efavirenz is highly bound (> 99%) to human plasma proteins, predominantly albumin.
Efavirenz se močno (> 99 %) veže na človeške plazemske beljakovine, predvsem na albumin.
1 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients.
1 Anemija je bila pogosta in sprememba obarvanosti kože (povečana pigmentacija) je bila zelo pogosta, ko so emtricitabin prejemali pediatrični bolniki.
These tumours are unlikely to be of relevance to humans.
Ti tumorji verjetno niso pomembni za človeka.
This leaflet was last revised in .
Navodilo je bilo nazadnje revidirano dne.
One tablet taken each day by mouth.
Ena tableta na dan, ki jo zaužijete skozi usta.
Atripla contains three active substances that are used to treat human immunodeficiency virus (HIV) infection:
Zdravilo Atripla vsebuje tri učinkovine, ki se uporabljajo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV):
In such patients, interruption or discontinuation of treatment must be considered (see section 4.8).
Pri takih bolnikih je treba pretehtati možnost prekinitve ali prenehanja zdravljenja (glejte poglavje 4.8).
- if you have a history of liver disease, including chronic active hepatitis.
če ste v preteklosti imeli bolezen jeter, vključno s kroničnim aktivnim hepatitisom.
The use of Atripla in children and adolescents has not been studied.
Uporabe zdravila Atripla pri otrocih in mladostnikih niso preučevali.
- if your doctor has told you that you have high or low levels of electrolytes such as potassium or magnesium in your blood.
- če vam je zdravnik povedal, da imate v krvi visok ali nizek nivo elektrolitov, kot sta kalij ali magnezij.
Confirmatory testing by a more specific method such as gas chromatography/mass spectrometry is recommended in such cases.
V teh primerih je priporočeno izvesti potrjevalne preskuse, z bolj specifično metodo, kot je plinska kromatografija/masna spektrometrija.
- severe disturbances of electrolyte balance e.g. hypokalemia or hypomagnesemia.
- hudo motnjo elektrolitskega ravnotežja, npr. hipokaliemijo ali hipomagneziemijo.
-3.3 (-8.3% to 2.7%) patients with HIV-1 RNA < 200 copies/ml
-3,3 % (-8,3 % do 2,7 %) bolniki s HIV-1 RNA < 200 kopij/ml
• liver failure, in some cases leading to death or liver transplant.
• jetrna odpoved, ki v nekaterih primerih povzroči smrt ali zahteva presaditev jeter.
Renal clearance has been estimated to be approximately 210 ml/min, which is in excess of the glomerular filtration rate.
Ocenili so, da znaša ledvični očistek približno 210 ml/min, kar presega stopnjo glomerularne filtracije.
Decreases in bone mineral density of the hip were significantly greater in this group until 96 weeks.
Zmanjšanje mineralne gostote kosti v kolku je bilo v tej skupini pomembno večje v prvih 96 tednih.
Table 1: Interactions between Atripla or its individual components and other medicinal products
Tabela 1: Interakcije med zdravilom Atripla ali posameznimi učinkovinami zdravila in drugimi zdravili
Patients coinfected with HIV and HBV
Bolniki, sočasno okuženi z virusoma HIV in HBV
The clinical effect of this dose adjustment has not been adequately evaluated.
Klinični učinek te prilagoditve odmerka še ni ustrezno ovrednoten.
Efavirenz has a relatively long terminal half-life of at least 52 hours after single doses (see also data from bioequivalence study described above) and 40 to 55 hours after multiple doses.
Efavirenz ima relativno dolg končni razpolovni čas, vsaj 52 ur po enkratnem odmerku (glejte tudi podatke iz bioekvivalenčne študije, opisane zgoraj) in 40 do 55 ur po večkratnih odmerkih.
Atripla tablets should be swallowed whole with water, once daily.
Tableta Atripla se pogoltne cela, z vodo, enkrat na dan.
Taking these medicines with Atripla could cause serious or life-threatening side effects or stop these medicines from working properly.
Jemanje teh zdravil skupaj z zdravilom Atripla lahko povzroči resne ali smrtno nevarne neželene učinke ali pa prepreči pravilno delovanje teh zdravil.
This medicine is not a cure for HIV infection.
To zdravilo ne pozdravi okužbe z virusom HIV.
Despite the decrease in buprenorphine exposure, no patients exhibited withdrawal symptoms.
Kljub zmanjšanju izpostavljenosti buprenorfinu nobeden od bolnikov ni kazal odtegnitvenih simptomov.
• increased levels of creatine kinase in the blood that may result in muscle pain and weakness
• povišano raven kreatin-kinaze v krvi, ki lahko povzroči bolečino v mišicah in šibkost.
However, less than 1% of an efavirenz dose is excreted unchanged in the urine, so the impact of renal impairment on exposure to efavirenz is likely to be minimal.
Vendar pa se manj kot 1 % odmerka efavirenza izloči nespremenjenega v urinu, zato je verjetno vpliv ledvične okvare na izpostavljenost efavirenzu minimalen.
However, there was no increased risk of fractures or evidence for clinically relevant bone abnormalities over 144 weeks.
Vendar v 144 tednih ni bilo povečanega tveganja za zlome ali dokazov za klinično pomembne kostne anomalije.
Atripla may make hormonal contraceptives less likely to work.
Zaradi zdravila Atripla so lahko hormonski kontraceptivi manj učinkoviti.
A positive relationship between efavirenz concentration and QTc prolongation was observed.
Ugotovili so pozitivno povezavo med koncentracijo efavirenza in podaljšanjem interval QTc.
There have also been post-marketing reports of severe depression, death by suicide, delusions, psychosis-like behaviour, and catatonia.
V postmarketinškem obdobju so poročali tudi o hudi depresiji, smrti zaradi samomora, blodnjah, vedenju, podobnem psihozam in katatoniji.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Atripla treatment without talking to your doctor first.
Če ste hkrati okuženi z virusom HIV in virusom hepatitisa B, je zlasti pomembno, da ne prenehate jemati zdravila Atripla, ne da bi se prej posvetovali z zdravnikom.
If you are over 65 years of age and are prescribed Atripla, your doctor will monitor you carefully.
Če ste starejši od 65 let in vam zdravnik predpiše zdravilo Atripla, vas bo med zdravljenjem pozorno spremljal.
Parameters Test Reference
test referenca
• anaemia (low red blood cell count)
• anemija (majhno število rdečih krvničk);
Substitutions at RT positions 98, 100, 101, 108, 138, 188, 190 or 225 were also observed, but at lower frequencies, and often only in combination with K103N.
101, 108, 138, 188, 190 ali 225, vendar redkeje in pogosto le v kombinaciji s K103N.
Some patients accidentally taking 600 mg efavirenz twice daily have reported increased nervous system symptoms.
Nekateri bolniki, ki so pomotoma vzeli 600 mg efavirenza dvakrat na dan, so poročali o večjem pojavljanju simptomov živčevja.
If it is almost time (less than 12 hours) for your next dose anyway, do not take the missed dose.
Če je že skoraj čas (manj kot 12 ur) za naslednji odmerek, izpuščenega odmerka ne vzemite.
Since use of two NNRTIs proved not beneficial in terms of efficacy and safety, co-administration of Atripla and another NNRTI is not recommended.
Ker uporaba dveh zdravil iz skupine NNRTI ni pokazala koristi pri učinkovitosti in varnosti, sočasne uporabe zdravila Atripla in drugega zdravila iz skupine NNRTI ne priporočamo.
Cross-resistance profiles for efavirenz, nevirapine and delavirdine in vitro demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs.
Profili navzkrižne odpornosti na efavirenz, nevirapin in delavirdin in vitro so pokazali, da substitucija K103N povzroči izgubo občutljivosti za vse tri NNRTI-je.
Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and operating machinery.
Bolnike je treba poučiti, naj se v primeru teh simptomov izogibajo potencialno nevarnim opravilom, kakršna sta vožnja ali upravljanje s stroji.
Rare photoallergic dermatitis angioedema
Redki fotoalergijski dermatitis angioedem
In virologically suppressed patients, the clinical relevance of this reduction can be expected to be limited (see section 5.1).
Pričakuje se lahko, da bo pri bolnikih z virološko supresijo klinični pomen tega zmanjšanja omejen (glejte poglavje 5.1).
The mechanism of tumour formation and the potential relevance for humans are not known.
Mehanizem nastanka tumorjev in morebitni pomen za človeka nista znana.
In clinical controlled studies of efavirenz, nervous system symptoms of moderate to severe intensity were experienced by 19% (severe 2%) of patients, and 2% of patients discontinued therapy due to such symptoms.
V kontroliranih kliničnih študijah efavirenza je zmerne do hude simptome živčnega sistema doživelo 19 % (hude 2 %) bolnikov in 2 % bolnikov sta prenehala z zdravljenjem zaradi teh simptomov.
Insufficient safety data are available for children below 18 years of age.
Ni dovolj podatkov o varnosti pri otrocih, starih manj kot 18 let.
Pharmacokinetic studies have not been performed with efavirenz, emtricitabine or tenofovir in elderly patients (over 65 years of age).
Farmakokinetične študije z efavirenzom, emtricitabinom ali tenofovirjem niso bile izvedene pri starejših bolnikih (nad 65 let starosti).
In addition, your doctor may consider giving you an additional dose of efavirenz to treat your HIV infection.
Poleg tega vam bo zdravnik morda dal dodatni odmerek efavirenza za zdravljenje okužbe z virusom HIV.
Rosuvastatin is largely excreted unchanged via the faeces, therefore interaction with efavirenz is not expected.
Rosuvastatin se v glavnem izloča nespremenjen prek blata, zato interakcij z efavirenzom ni pričakovati.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Preobčutljivost za učinkovine ali katerokoli pomožno snov, navedeno v poglavju 6.1.
EU/1/07/430/001 30 film-coated tablets EU/1/07/430/002 90 (3 bottles of 30) film-coated tablets
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/430/001 30 filmsko obloženih tablet EU/1/07/430/002 90 (3 vsebniki po 30) filmsko obloženih tablet
• a feeling of spinning or tilting (vertigo), whistling, ringing or other persistent noise in the ears
• občutek vrtenja ali nagibanja (vrtoglavica), žvižganje, piskanje ali drug vztrajen zvok v ušesu;
However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.
Vendar so se po pričakovanju zvišanja AST in ALT v tej skupini bolnikov pojavila pogosteje kot v splošni populaciji bolnikov, okuženih z virusom HIV.
As a general rule, it is recommended that HIV infected women do not breast-feed their infants in order to avoid transmission of HIV to the infant.
Na splošno se priporoča, da ženske, okužene z virusom HIV, ne dojijo, da se prepreči prenos virusa HIV na dojenčka.
Both HIV and the ingredients of Atripla may pass through breast milk and cause serious harm to your baby.
Virus HIV in sestavine zdravila Atripla lahko preidejo v materino mleko ter resno škodijo otroku.
In some cases, your doctor may need to adjust your dose or check your blood levels.
V nekaterih primerih bo zdravnik morda moral prilagoditi odmerek zdravila ali preveriti njegovo raven v krvi.
Rare osteomalacia (manifested as bone pain and infrequently contributing to fractures)2,4, myopathy2
Redki osteomalacija (ki se kaže kot bolečine v kosteh in redko prispeva k zlomom)2,4, miopatija4
Studies conducted with other medicinal products
Študije, opravljene z drugimi zdravili
In the open-label extended phase of study GS-01-934, where patients received Atripla on an empty stomach, 3 additional cases of resistance were seen.
V odprti podaljšani fazi študije GS-01-934, kjer so bolniki dobivali zdravilo Atripla na tešče, so opazili 3 dodatne primere odpornosti.
Tenofovir is primarily excreted by the kidneys by both filtration and an active tubular transport system with approximately 70 to 80% of the dose excreted unchanged in urine following intravenous administration.
Tenofovir se primarno izloča skozi ledvice tako z glomerulno filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenskem vnosu približno 70-80 % odmerka izloči nespremenjenega z urinom.
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.
Ne obravnava se, kot da je vzročno povezana z dizoproksiltenofoviratom v odsotnosti tega stanja.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastičnem vsebniku in škatli poleg oznake „EXP“.
Sufficient data on the tolerability of efavirenz with low-dose ritonavir (100 mg, once or twice daily) are not available.
Zadostnih podatkov o prenašanju efavirenza v kombinaciji z majhnimi odmerki ritonavirja (100 mg, enkrat ali dvakrat na dan) ni na voljo.
Other macrolide antibiotics, such as erythromycin, have not been studied in combination with Atripla.
Drugih makrolidnih antibiotikov, kot je eritromicin, v kombinaciji z zdravilom Atripla niso preučevali.
- any signs of skin rash.
kakršnekoli znake kožnega izpuščaja.
The frequency of this is unknown (see section 4.4).
Pogostnost tega učinka ni znana (glejte poglavje 4.4).
There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh-Turcotte Class B or C) affects efavirenz pharmacokinetics.
Ni bilo dovolj podatkov, da bi ugotovili, ali zmerna ali huda jetrna okvara (razreda B ali C po ChildPughTurcotteovi lestvici) vpliva na farmakokinetiko efavirenza.
Possible serious side effects: tell your doctor immediately
Možni resni neželeni učinki: takoj se posvetujte z zdravnikom
Up to 30% of the emtricitabine dose and approximately 10% of the tenofovir dose can be removed by haemodialysis.
S hemodializo se lahko odstrani do 30 % odmerka emtricitabina in približno 10 % odmerka tenofovirja.
Refer to section 2 “Atripla contains sodium”.
Glejte poglavje 2 „Zdravilo Atripla vsebuje natrij“.
Your doctor will check your cholesterol levels and will consider changing the dose of your statin, if needed.
Zdravnik bo preveril ravni holesterola in vam po potrebi spremenil odmerek statina.
Both the K65R and M184V/I mutation remain fully susceptible to efavirenz.
Mutaciji K65R in M184V/I sta popolnoma občutljivi za efavirenz.
If you have taken Atripla during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.
Če ste zdravilo Atripla jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
Your doctor may then conduct blood tests at regular intervals in order to check how well your liver is working (see section 3, If you stop taking Atripla).
Zato bo zdravnik morda v rednih presledkih opravil krvne preiskave, da preveri, kako dobro delujejo vaša jetra (glejte poglavje 3, Če ste prenehali jemati zdravilo Atripla).
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor.
V drugih študijah (prospektivne in presečne) so najbolj izrazito zmanjšanje MGK opazili pri bolnikih, zdravljenih z dizoproksiltenofoviratom kot del režima, ki je vseboval okrepljenega zaviralca proteaze.
Following intravenous administration the volume of distribution of emtricitabine was approximately 1.4 l/kg.
Po intravenskem odmerku je volumen porazdelitve emtricitabina znašal približno 1,4 l/kg.
The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.
Klinični pomen te povezave ni znan, vendar pa možnost za povečanje pogostnosti in resnosti z efavirenzom povezanih neželenih učinkov ne more biti izključena.
Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, antivirusna zdravila za zdravljenje infekcij s HIV-om, kombinacije, oznaka ATC: J05AR06.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil (two of the three components of Atripla).
Pri nekaterih bolnikih so krvne preiskave ali simptomi pokazali, da se je hepatitis poslabšal po prenehanju jemanja emtricitabina ali dizoproksiltenofovirata (dve od treh učinkovin zdravila Atripla).
Efavirenz, one of the active components of Atripla, may remain in your blood for a time after therapy is stopped.
Efavirenz, ena izmed učinkovin zdravila Atripla, lahko ostane v krvi še nekaj časa po prenehanju zdravljenja.
Data on the clinical translation of the decrease in pharmacokinetic exposure are not available.
Podatki o kliničnem pomenu zmanjšanja farmakokinetične izpostavljenosti niso na voljo.
Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited.
Izkušnje z efavirenzom pri bolnikih, ki so prenehali jemati druga protiretrovirusna zdravila razreda NNRTI, so omejene.
Biliary fibrosis has been observed in rats.
Pri podganah so opazili biliarno fibrozo.
The silica gel desiccant is contained in a separate sachet and should not be swallowed.
Sušilno sredstvo iz silikagela je v posebni vrečki in ga ne smete pogoltniti.
Concomitant use of posaconazole and Atripla should be avoided unless the benefit to the patient outweighs the risk.
Sočasni uporabi pozakonazola in zdravila Atripla se je treba izogibati, razen če so koristi za bolnika večje od tveganja.
Efavirenz may also cause impaired concentration and/or somnolence.
Efavirenz lahko povzroči tudi motnje koncentracije in/ali somnolenco.
Immune system disorders: Common allergic reaction
Bolezni imunskega sistema: Pogosti alergijske reakcije
The pharmacokinetics of emtricitabine and tenofovir are similar in male and female patients.
Farmakokinetične lastnosti emtricitabina in tenofovirja so podobne pri bolnikih moškega in ženskega spola.
• breakdown of muscle, muscle pain or weakness
• razgradnja mišic, bolečina v mišicah ali šibkost;
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).
Biotransformacija emtricitabina vključuje oksidacijo tiolne skupine, pri čemer nastanejo diastereomeri 3'-sulfoksida (približno 9 % odmerka), in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (približno 4 % odmerka).
PVR (KM): Pure virologic response assessed using the Kaplan Meier (KM) method M: Missing
PVR(KM): čisti virološki odziv, ocenjen po metodi Kaplan Meier (KM).
The safety and efficacy of Atripla have not been studied for the treatment of chronic HBV infection.
Varnosti in učinkovitosti zdravila Atripla pri zdravljenju kronične okužbe s HBV niso raziskovali.
Efavirenz plasma exposure may be increased in patients with homozygous G516T genetic variant of the CYP2B6 isozyme.
Plazemska izpostavljenost efavirenzu je lahko povečana pri bolnikih s homozigotno genetsko različico G516T izocima CYP2B6.
Because of interpatient variability in these parameters and concerns regarding development of resistance, HIV treatment guidelines should be consulted, also taking into consideration the reason for discontinuation.
Zaradi razlik pri teh parametrih med posameznimi bolniki in skrbi zaradi razvoja odpornosti je treba upoštevati smernice za zdravljenje okužbe z virusom HIV hkrati z razlogom za prekinitev zdravljenja.
Common cerebellar coordination and balance disturbances3, somnolence (2.0%)3, headache (5.7%)3, disturbance in attention (3.6%)3, dizziness dizziness headache
Pogosti motnje cerebelarne koordinacije in ravnotežja3, somnolenca (2,0 %)3, glavobol (5,7 %)3, motnje pozornosti (3,6 %)3, omotica omotica glavobol
Cholesterol levels should be periodically monitored.
Raven holesterola je treba redno spremljati.
The clinical outcome of this observed reduction of boceprevir trough concentrations has not been directly assessed.
Klinični izid opazovanega zmanjšanja najmanjše koncentracije boceprevira še ni bil neposredno ovrednoten.
In vitro binding of emtricitabine to human plasma proteins is < 4% and independent of concentrations over the range of 0.02 to 200 µg/ml.
In vitro je bila vezava emtricitabina na človeške plazemske beljakovine < 4 % in neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
These immunosuppressants are not anticipated to impact exposure of efavirenz.
Ni pričakovati vpliva teh imunosupresivov na izpostavljenost efavirenzu.
This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time.
Zelo je pomembno, da ne prekinete zdravljenja z zdravilom Atripla, saj se količina virusa lahko začne večati, tudi če zdravilo prenehate jemati samo za kratek čas.
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%).
Emtricitabin se primarno izloča skozi ledvica - celoten odmerek se izloči z urinom (približno 86 %) in blatom (približno 14 %).